BioMarin Pharmaceutical Inc. (FRA:BM8)
Germany · Delayed Price · Currency is EUR 47.62
0.00 (0.00%)
At close: Nov 28, 2025
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,040 employees as of December 31, 2024. The number of employees decreased by 361 or -10.61% compared to the previous year.
Employees
3,040
Change (1Y)
-361
Growth (1Y)
-10.61%
Revenue / Employee
€867,440
Profits / Employee
€145,905
Market Cap
9.09B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3,040 | -361 | -10.61% |
| Dec 31, 2023 | 3,401 | 319 | 10.35% |
| Dec 31, 2022 | 3,082 | 37 | 1.22% |
| Dec 31, 2021 | 3,045 | -14 | -0.46% |
| Dec 31, 2020 | 3,059 | 58 | 1.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 318,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 103,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
BioMarin Pharmaceutical News
- 13 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 20 days ago - BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England - PRNewsWire
- 21 days ago - BMRN February 2026 Options Begin Trading - Nasdaq
- 25 days ago - BioMarin Pharmaceutical (BMRN) Downgraded by Stifel: Target Price Lowered | BMRN Stock News - GuruFocus
- 4 weeks ago - BioMarin (BMRN) Achieves FDA Priority Review for Expanded Use of Palynziq - GuruFocus
- 4 weeks ago - FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria - PRNewsWire
- 4 weeks ago - Beyond the Balance Sheet: What SWOT Reveals About BioMarin Pharmaceutical Inc (BMRN) - GuruFocus
- 4 weeks ago - Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday - The Motley Fool